Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)
Phase of Trial: Phase 0
Latest Information Update: 15 Dec 2017
Price : $35 *
At a glance
- Drugs Thrombosomes (Primary)
- Indications Haemorrhage; Wounds
- Focus Adverse reactions; First in man
- Sponsors Cellphire
- 11 Dec 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2016.
- 10 Jun 2016 Status changed from recruiting to active, no longer recruiting.